Project Grant R01CA303254
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60208, USA
Similar Awards
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- The National Cancer Institute awarded Northwestern University a $1.139 million Cooperative Agreement (UG1CA308665) on April 28, 2026, under the Cancer Treatment Research program (CFDA 93.395) to serve as a Lead Academic Participating Site within the NCI National Clinical Trials Network. The Robert H. Lurie Comprehensive Cancer Center at Northwestern will drive innovation in cancer clinical trials, particularly early-phase and multi-center studies, while expanding access to treatments across...
- The National Cancer Institute awarded Northwestern University $660,525 in project grant funding on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer immunostimulatory spherical nucleic acids for B cell adoptive therapy against prostate cancer. The funded research develops a novel strategy to sensitize immunologically "cold" prostate tumors to immune checkpoint blockade by training peripheral B cells ex vivo with immunostimulatory spherical nucleic...
- The National Cancer Institute awarded the University of Miami $614,453 on August 24, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing Number) to develop anti-ST2 theranostic nanobodies for colorectal cancer immunotherapy. The award funds development and characterization of murine and human single-domain antibodies (nanobodies) targeting ST2 (interleukin-33 receptor), a novel immune checkpoint target for advanced colorectal cancer. Work includes generating...
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded Northwestern University $631,487 under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, to conduct mechanistic research on LKB1-mutant lung cancer and therapeutic resistance. The research combines genomics and mass spectrometry approaches with lung cancer cell lines and mouse models to determine how LKB1 loss regulates HDAC3/NKX2-1 complex function, to test whether LKB1 status predicts response to combined KRAS pathway...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute at the Department of Health and Human Services awarded New York University School of Medicine a $671,426 cooperative agreement on September 3, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the Non-Invasive Post-Polypectomy Surveillance Study (NIPPSS). The award funds a two-phase investigation into surveillance strategies following colorectal polyp removal. The UG3 pilot phase will optimize a fecal immunochemical test (FIT)...